Use of stem cell factor interleukin-6 and soluble interleukin-6 receptor to induce the development of hematopoietic stem cells
Patent Number: 5610056
Date of First Priority Issue: Wednesday November 16th, 1994
Date Issued: Tuesday March 11th, 1997
Assignee: Amgen Inc. (Thousand Oaks, CA); Tosoh Corporation (Tokyo, JP)
Inventor: Nakahata, Tatsutoshi (Tokyo, JP)
From Class: Differentiation
Comments: No comments
This patent teaches that administration of stem cell factor, IL6, and IL6 soluble receptor, to hematopoietic stem cells, causes the hematopoietic stem cells to differentiate into erythroid precursors, and into erythrocytes.
This patent is useful for parties seeking to generate red blood cells in vitro.
View this patent on the USPTO website.
Added to StemCellPatents.com on Monday October 16th, 2006
Social & Bookmarking:
Add Comment
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.